Form 4: Adicet Bio Director's Stock Option Repricing Rescinded

Michael Kauffman, a director at Adicet Bio, had his stock options repricing rescinded, reverting them to their original exercise prices.

Summary

• On August 21, 2024, Adicet Bio's Board of Directors approved the rescission of the August 2023 stock option repricing for certain non-employee directors, including Michael Kauffman.
• The affected stock options have been reverted to their original exercise prices as established at the time of the grant.
• Kauffman's transactions involved stock options with exercise prices of $2.14 and $9.39.
• Some options vest monthly starting November 17, 2021, while others are fully vested as of August 21, 2024.
• The transactions were exempt under Rule 16b-6(d) and Rule 16b-3 of the Exchange Act.

Sentiment

Score: 6

Explanation: The document describes a routine adjustment to stock options, which is neither particularly positive nor negative. The sentiment is neutral.

Positives

• The rescission of the repricing simplifies the option structure for non-employee directors.
• Reverting to original exercise prices may align director incentives with long-term shareholder value.

Industry Context

Stock option repricing is a common practice in the biotech industry to retain and incentivize key personnel, especially during periods of stock price volatility. The rescission suggests a potential change in the company's compensation strategy or a reassessment of the fairness of the repricing.

Comparison to Industry Standards

• Stock option grants to directors are a standard practice across the biotechnology industry.
• Companies like Juno Therapeutics (acquired by Celgene) and Kite Pharma (acquired by Gilead) also used stock options as part of their director compensation packages.
• The specific terms of vesting and exercise prices vary widely based on company size, stage of development, and overall compensation philosophy.

Stakeholder Impact

• The rescission of the stock option repricing may have a minor impact on shareholder perception of executive compensation.
• The change affects the potential future compensation of the non-employee directors.

Key Dates